Perspective Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 23, 2026, 10:52 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedPerspective Therapeutics Reports Updated Phase 1/2a VMT-α-NET Data at ESMO: 50% ORR in 6.0 mCi Cohort, 72% PFS at 18 Months
8-KOct. 8, 2026, 6:28 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedPerspective Therapeutics Granted FDA Fast Track Designation for PSV359 in FAP-Positive Solitary Fibrous Tumors
8-KOct. 1, 2026, 4:08 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedPerspective Therapeutics Updates Corporate Presentation With Pipeline Data for VMT-α-NET, VMT01 and PSV359, No Financial Results Disclosed
SCHEDULE 13D/ASept. 23, 2026, 4:19 p.m. ETView on SEC.gov
8-KSept. 14, 2026, 6:20 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
4Sept. 8, 2026, 4:51 p.m. ETView on SEC.gov
8-KSept. 8, 2026, 5:16 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
4Sept. 4, 2026, 5 p.m. ETView on SEC.gov
4Sept. 4, 2026, 4:58 p.m. ETView on SEC.gov
SCHEDULE 13D/ASept. 4, 2026, 4:48 p.m. ETView on SEC.gov
4Sept. 3, 2026, 4:54 p.m. ETView on SEC.gov
4Sept. 2, 2026, 4:36 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 13, 2026, 7:58 p.m. ETView on SEC.gov
10-QAug. 10, 2026, 4:34 p.m. ETView on SEC.gov
8-KAug. 10, 2026, 4:30 p.m. ETView on SEC.gov
Results of operations and financial condition · Other events · Financial statements and exhibits
SCHEDULE 13GAug. 7, 2026, 10:42 a.m. ETView on SEC.gov
8-KAug. 3, 2026, 4:15 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
SCHEDULE 13GJuly 29, 2026, 3:19 p.m. ETView on SEC.gov